Our Group organises 3000+ Global Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ ºÚÁÏÍø Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
The last thirty years have registered a progressive and dramatic increase in the incidence of type 2 diabetes mellitus (T2DM)
and obesity in the population of USA and developed countries, as well as developing countries. Combined, these two
medical conditions affect about one-third of the adult population, as well as adolescent and children, with some differences,
at times significant, in terms of age, race, ethnicity, and gender. Currently, it is estimated that between 500 million to 1 billion
people worldwide are obese, diabetic, or at risk of developing one or both these conditions. The interplay between obesity
and T2DM onset are not completely understood, making difficult to establish short- and long-term health guidelines and
therapeutic approaches that can help containing and possibly reversing the incidence and progression of these conditions.
More worrisome, the incidence of the metabolic syndrome has also increased in proportion over the same period of time. The
term �metabolic syndrome� refers to a group of risk factors that raises significantly the risk for heart disease and other health
problems including stroke, diabetes, and particular forms of cancer. Currently, liver steatosis, with or without inflammation
(steatohepatitis) and progression to NAFLD is considered pathognomonic of metabolic syndrome, and represents the most
common manifestation of the disease. The etiology of these diseases is multi-facet. From the pathological standpoint, metabolic
syndrome, NAFLD, obesity and T2DM are characterized by major lipid dysmetabolism both systemic and within liver and
adipose tissue. Inflammation is a key component of these pathologies, in that enhanced levels of inflammatory cytokines have
been observed both systemically and within specific organs, in which they impair insulin responsiveness and hematic glucose
homeostasis.
Altogether, metabolic syndrome, NAFLD, obesity and insulin resistance pose major financial burdens on the affected
individuals, and on the medical and productive systems of the various countries. The predisposition to various complications
and the associated financial costs for their treatment point to the necessity to better understand the underlying causes of these
diseases and to identify more effective therapeutic approaches and treatments.
Biography
Andrea Romani obtained his medical degree from the University of Siena, Italy and his PhD from the University of Turin, Italy. Upon completing his postdoctoral studies under Dr. Scarpa, he joined the faculty in the Department of Physiology and Biophysics, Case Western Reserve University, where he is currently Associate Professor. Dr. Romani has published over 90 peer review articles in high profile journals together with numerous invited reviews and book chapters. He is currently serving as an Editorial Board Member and an ad hoc reviewer for numerous international journals.